Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19190623 | ALGAL BIOFILM HARVESTING METHOD CAPABLE OF REDUCING RELEASE OF PLANKTONIC MICROALGAE | April 2025 | June 2025 | Allow | 2 | 0 | 0 | Yes | No |
| 19061532 | EXTRACTION OF ANTIMETHANOGENIC COMPOUNDS | February 2025 | June 2025 | Allow | 4 | 1 | 1 | Yes | No |
| 19044249 | Epigen AU/11: A NATURAL MATRIX FOR RESTORING HOMEOSTASIS IN CANCER CELL-INFILTRATED TISSUE | February 2025 | July 2025 | Allow | 5 | 0 | 1 | Yes | No |
| 18772054 | PARABURKHOLDERIA SP. AND USE THEREOF | July 2024 | July 2025 | Allow | 12 | 1 | 1 | Yes | No |
| 18397091 | COMPOSITIONS AND METHODS FOR IN UTERO DELIVERY | December 2023 | September 2024 | Allow | 8 | 2 | 0 | Yes | No |
| 18534335 | POLYHYDROXYALKANOIC ACID COMPOSITIONS AND METHODS FOR GENERATING SAME | December 2023 | July 2025 | Allow | 19 | 1 | 1 | Yes | No |
| 18531157 | Parallel Cell Processing Method and Facility | December 2023 | June 2025 | Allow | 18 | 2 | 1 | Yes | No |
| 18501227 | APPLICATION OF ANTARCTIC RED PIGMENT IN PREPARATION OF DRUGS FOR TREATMENT AND PREVENTION OF HYPERURICEM | November 2023 | February 2026 | Abandon | 28 | 4 | 0 | Yes | No |
| 18376832 | Carbon Capture by Algal Inoculation of Ocean Ice and/or Sea Ice | October 2023 | June 2025 | Allow | 20 | 0 | 1 | Yes | No |
| 18376827 | MATERIALS AND METHODS FOR ALGAL INOCULATION TO EFFECT DIRECT CAPTURE OF CARBON DIOXIDE FROM AIR | October 2023 | June 2025 | Allow | 20 | 0 | 1 | Yes | No |
| 18352386 | THRAUSTOCHYTRIDS, FATTY ACID COMPOSITIONS, AND METHODS OF MAKING AND USES THEREOF | July 2023 | May 2025 | Allow | 22 | 2 | 1 | Yes | No |
| 18321701 | COMPOSITION AND METHODS FOR HAIR REGROWTH | May 2023 | March 2026 | Abandon | 33 | 0 | 1 | No | No |
| 18030592 | COMPOSITION FOR PROMOTING HAIR GROWTH AND/OR INHIBITING HAIR LOSS | April 2023 | February 2026 | Abandon | 34 | 1 | 0 | No | No |
| 18005612 | TROPHIN GENOME EDITING FOR TREATING DUCHENNE MUSCULAR DYSTROPHY (DMD) | January 2023 | March 2026 | Allow | 38 | 1 | 0 | No | No |
| 18000676 | TYPE I-C CRISPR SYSTEM FROM NEISSERIA LACTAMICA AND METHODS OF USE | December 2022 | January 2026 | Allow | 37 | 1 | 0 | No | No |
| 17996438 | COMPOSITIONS FOR USE IN TREATING AUTOSOMAL DOMINANT BEST1-RELATED RETINOPATHIES | October 2022 | December 2025 | Allow | 38 | 1 | 0 | No | No |
| 17912190 | BACTERIUM OF THE CHRISTENSENELLACEAE FAMILY IN THE PREVENTION AND/OR TREATMENT OF HYPERTRIGLYCERIDEMIA | September 2022 | March 2026 | Abandon | 42 | 1 | 1 | Yes | No |
| 17930890 | NUCLEIC ACID CONSTRUCT SET, KIT, DETECTION METHOD AND METHOD FOR PREDICTING DRUG EFFECT | September 2022 | December 2025 | Allow | 39 | 1 | 0 | No | No |
| 17824603 | METHOD FOR INDUCING DOPAMINERGIC NEURON PROGENITOR CELLS | May 2022 | October 2025 | Allow | 40 | 1 | 1 | No | No |
| 17733875 | DEVICES AND METHODS FOR ISOLATING TUMOR INFILTRATING LYMPHOCYTES AND USES THEREOF | April 2022 | January 2023 | Allow | 8 | 1 | 0 | No | No |
| 17718870 | ADENO-ASSOCIATED VIRUS VARIANT CAPSIDS AND METHODS OF USE THEREOF | April 2022 | December 2022 | Allow | 8 | 1 | 0 | No | No |
| 17429553 | METHOD FOR TREATING OSTEOARTHRITIS WITH MESENCHYMAL STEM CELL EXOSOMES | August 2021 | June 2025 | Allow | 47 | 1 | 3 | Yes | No |
| 17342281 | AMINE CATIONIC LIPIDS AND USES THEREOF | June 2021 | May 2025 | Abandon | 47 | 0 | 1 | No | No |
| 17327620 | THERAPEUTIC USES OF GENOME EDITING WITH CRISPR/Cas SYSTEMS | May 2021 | October 2023 | Abandon | 29 | 3 | 0 | No | Yes |
| 17327606 | THERAPEUTIC USES OF GENOME EDITING WITH CRISPR/Cas SYSTEMS | May 2021 | July 2023 | Abandon | 26 | 2 | 0 | No | No |
| 17323658 | BOS TAURUS CELL TYPE 'HO840003210132823' | May 2021 | October 2023 | Abandon | 29 | 1 | 0 | No | No |
| 17228844 | EPCAM ANTIBODY AND CAR-T CELLS | April 2021 | March 2023 | Allow | 23 | 1 | 0 | Yes | No |
| 17221569 | TREATMENT METHODS | April 2021 | October 2023 | Abandon | 30 | 0 | 1 | No | No |
| 17092999 | Methods of Preserving Blood Samples for Mass Screening to Detect at-Risk Individuals for Autoimmune Diseases | November 2020 | December 2023 | Abandon | 37 | 0 | 1 | No | No |
| 16977403 | CULTURE SYSTEM FOR CHEMICALLY INDUCING GENERATION OF PLURIPOTENT STEM CELLS AND CHEMICAL REPROGRAMMING METHOD USING SAME | September 2020 | December 2023 | Abandon | 40 | 1 | 0 | No | No |
| 16922981 | POINT-OF-CARE AND/OR PORTABLE PLATFORM FOR GENE THERAPY | July 2020 | October 2023 | Abandon | 39 | 1 | 0 | No | No |
| 16844723 | METHODS FOR NUCLEAR REPROGRAMMING USING SYNTHETIC TRANSCRIPTION FACTORS | April 2020 | February 2023 | Allow | 34 | 1 | 0 | Yes | No |
| 16651918 | IN VITRO METHOD OF MRNA DELIVERY USING LIPID NANOPARTICLES | March 2020 | May 2025 | Abandon | 60 | 4 | 1 | Yes | No |
| 16647242 | OSTEOINDUCTIVE PEPTIDES, COMPOSITIONS, IMPLANTS, AND METHODS OF USE | March 2020 | October 2023 | Abandon | 43 | 0 | 1 | No | No |
| 16645561 | New Therapy for Pompe Disease | March 2020 | December 2023 | Abandon | 46 | 1 | 1 | No | No |
| 16746205 | LIPID-BASED COMPOSITIONS OF ANTIINFECTIVES FOR TREATING PULMONARY INFECTIONS AND METHODS OF USE THEREOF | January 2020 | April 2023 | Abandon | 39 | 1 | 0 | No | No |
| 16730951 | METHODS AND COMPOSITIONS FOR CHIMERIC ANTIGEN RECEPTOR TARGETING CANCER CELLS | December 2019 | July 2023 | Abandon | 43 | 0 | 0 | No | No |
| 16625064 | CELL REPROGRAMMING METHODS FOR PRODUCING CHONDROCYTES | December 2019 | August 2023 | Abandon | 44 | 0 | 1 | No | No |
| 16076443 | COMPOSITION FOR PREVENTING AND TREATING ARTHRITIS, INCLUDING DNA FRAGMENT MIXTURE AND MATRIX METALLOPROTEINASE PRODUCTION INHIBITOR | August 2019 | May 2021 | Abandon | 33 | 3 | 0 | No | No |
| 16483876 | NOVEL T-CELL RECEPTOR | August 2019 | October 2022 | Allow | 38 | 1 | 1 | Yes | No |
| 16464012 | H-1 PV EXPRESSING RNAI EFFECTORS TARGETING CDK9 | May 2019 | April 2023 | Abandon | 46 | 2 | 0 | No | No |
| 16347327 | REMOTE CONTROL OF LIGHT-TRIGGERED VIROTHERAPY | May 2019 | February 2025 | Abandon | 60 | 4 | 0 | No | No |
| 16292922 | METHODS OF CONTROLLING RED BLOOD CELL PRODUCTION | March 2019 | October 2023 | Abandon | 55 | 3 | 1 | No | No |
| 16278336 | Compositions and Methods for Cancer Immunotherapy | February 2019 | December 2019 | Abandon | 10 | 0 | 0 | No | No |
| 16320186 | TREATING CANCER | January 2019 | May 2023 | Abandon | 51 | 4 | 1 | No | No |
| 16319791 | SPATIOTEMPORAL REGULATORS | January 2019 | January 2023 | Abandon | 48 | 3 | 0 | No | No |
| 16319749 | Compositions and Methods for Inhibiting Stem Cell Aging | January 2019 | January 2023 | Abandon | 47 | 2 | 1 | No | No |
| 16315032 | ADENO-ASSOCIATED VIRUS VIRIONS WITH VARIANT CAPSID AND METHODS OF USE THEREOF | January 2019 | September 2022 | Allow | 44 | 1 | 1 | Yes | No |
| 16205277 | PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF PULMONARY DISEASE INCLUDING MESENCHYMAL STEM CELL-DERIVED ARTIFICIAL NANOSOMES | November 2018 | December 2022 | Abandon | 48 | 4 | 0 | No | No |
| 16185055 | MESENCHYMAL STEM CELL THERAPY FOR SPINAL MUSCULAR ATROPHY | November 2018 | January 2022 | Abandon | 38 | 2 | 0 | No | No |
| 16088570 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF ALS | September 2018 | June 2023 | Abandon | 57 | 4 | 0 | Yes | No |
| 16036368 | METHOD OF PRODUCING UNDENATURED COLLAGEN FROM CARTILAGE WITH LOW TEMPERATURE HYDROLYSIS | July 2018 | July 2023 | Abandon | 60 | 3 | 0 | No | Yes |
| 16061982 | COMPOSITIONS AND METHODS FOR REGULATABLE ANTIBODY EXPRESSION | June 2018 | June 2025 | Abandon | 60 | 6 | 1 | No | Yes |
| 15772023 | REGULATABLE EXPRESSION USING ADENO-ASSOCIATED VIRUS (AAV) | April 2018 | April 2022 | Abandon | 48 | 2 | 1 | No | Yes |
| 15767313 | STABILIZED ANTI-CANCER COLD ATMOSPHERIC PLASMA (CAP)-STIMULATED MEDIA AND METHODS FOR PREPARING AND USING THE SAME | April 2018 | January 2022 | Abandon | 46 | 2 | 1 | No | No |
| 15835957 | DELIVERY OF TARGET SPECIFIC NUCLEASES | December 2017 | November 2024 | Abandon | 60 | 7 | 1 | No | Yes |
| 15597063 | COMPOSITIONS FOR THE DELIVERY OF TRNA AS NANOPARTICLES AND METHODS OF USE THEREWITH | May 2017 | June 2023 | Abandon | 60 | 7 | 1 | Yes | Yes |
| 15351017 | Scaffold Delivery of Immune Suppressors and Transplant Material for Control of Transplant Rejection | November 2016 | January 2019 | Abandon | 26 | 1 | 0 | No | No |
| 15336783 | METHOD OF DIFFERENTIATING MAMMALIAN PROGENITOR CELLS INTO INSULIN PRODUCING PANCREATIC ISLET CELLS | October 2016 | December 2018 | Abandon | 25 | 1 | 0 | No | No |
| 15220914 | METHODS AND COMPOSITIONS FOR GENE INACTIVATION | July 2016 | August 2019 | Abandon | 37 | 1 | 0 | No | No |
| 15189914 | CO-CULTURE OF PLACENTAL CELLS AND STEM CELLS FROM A SECOND SOURCE | June 2016 | October 2019 | Abandon | 39 | 2 | 0 | Yes | Yes |
| 15188264 | TRANSGENIC ANIMAL MODEL OF MOOD DISORDERS | June 2016 | December 2018 | Abandon | 30 | 2 | 0 | No | No |
| 15052487 | CONDITIONALLY ACTIVE CHIMERIC ANTIGEN RECEPTORS FOR MODIFIED T-CELLS | February 2016 | August 2019 | Abandon | 42 | 2 | 1 | Yes | No |
| 14997121 | CELLS HAVING DISRUPTED EXPRESSION OF PROTEINS INVOLVED IN ADME AND TOXICOLOGY PROCESSES | January 2016 | December 2018 | Abandon | 35 | 2 | 2 | No | No |
| 14993194 | TRANSPLANTATION OF CELLS INTO THE NASAL CAVITY AND THE SUBARACHNOID CRANIAL SPACE | January 2016 | April 2018 | Abandon | 28 | 3 | 0 | No | No |
| 14892547 | MULTICOLOR FLOW CYTOMETRY METHOD FOR IDENTIFYING A POPULATION OF CELLS, IN PARTICULAR MESENCHYMAL STEM CELLS | November 2015 | March 2019 | Abandon | 40 | 5 | 1 | No | No |
| 14935371 | MULTI-STEP METHOD FOR FABRICATING TISSUE ENGINEERING BONE | November 2015 | October 2018 | Abandon | 36 | 1 | 0 | No | No |
| 14414171 | Honey-based dressing for the treatment of wounds and burns | September 2015 | November 2017 | Abandon | 34 | 0 | 1 | No | No |
| 14616167 | POST-PARTUM MAMMALIAN PLACENTA, ITS USE AND PLACENTAL STEM CELLS THEREFROM | February 2015 | March 2019 | Abandon | 50 | 4 | 0 | No | Yes |
| 14417823 | INTRATHECAL DELIVERY OF RECOMBINANT ADENO-ASSOCIATED VIRUS 9 | January 2015 | August 2018 | Abandon | 42 | 3 | 1 | Yes | Yes |
| 14536603 | MATERIALS AND METHODS FOR MAKING A RECESSIVE GENE DOMINANT | November 2014 | April 2019 | Abandon | 53 | 4 | 1 | No | Yes |
| 14508610 | Methods And Compositions Comprising A Drosophila Model Of Amyotrophic Lateral Sclerosis | October 2014 | July 2018 | Abandon | 45 | 4 | 1 | No | No |
| 14263158 | Transgenic Non-Human Assay Vertebrates, Assays and Kits | April 2014 | February 2019 | Abandon | 57 | 3 | 1 | Yes | No |
| 14351481 | CHIMERIC NON-HUMAN ANIMAL CARRYING HUMAN HEPATOCYTE | April 2014 | October 2015 | Allow | 19 | 2 | 0 | No | No |
| 11203461 | HOMOGENEOUS ASSAY SYSTEM | August 2005 | September 2008 | Allow | 37 | 4 | 0 | Yes | No |
| 11103139 | BICYCLIC HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | April 2005 | April 2008 | Allow | 36 | 1 | 1 | Yes | No |
| 11031450 | METHODS AND COMPOSITIONS FOR MODULATING GLUCONEOGENESIS USING PGC-1 | January 2005 | September 2007 | Allow | 32 | 1 | 1 | Yes | No |
| 10897592 | RAPID IDENTIFICATION OF BACTERIA FROM POSITIVE BLOOD CULTURES | July 2004 | November 2006 | Allow | 28 | 2 | 0 | No | No |
| 10481943 | GEDAP METHOD (GENOTYPING BASED ON DIAGNOSTIC AMPLIFICATION PRODUCTS) FOR DETECTING AND/OR PREVENTING GENOTYPING ERRORS FROM AMPLIFICATION PRODUCTS OF A POLYMORPHIC FOCUS | April 2004 | March 2008 | Allow | 51 | 2 | 0 | No | No |
| 10486645 | ISOTHERMAL CHIMERIC PRIMER NUCLEIC ACID AMPLIFICATION METHODS USING BLOCKING OGLIONUCLEOTIDE | February 2004 | September 2005 | Allow | 19 | 1 | 0 | Yes | No |
| 10636509 | ORIENTATION-DIRECTED CONSTRUCTION OF PLASMIDS | August 2003 | May 2007 | Allow | 45 | 1 | 0 | No | No |
| 10302098 | POLYNUCLEOTIDE THERAPY | November 2002 | January 2009 | Allow | 60 | 4 | 1 | No | No |
| 10294191 | NOVEL GHRELIN ALLELES AND USE OF THE SAME FOR GENETICALLY TYPING ANIMALS | November 2002 | January 2006 | Allow | 38 | 1 | 1 | Yes | No |
| 09961089 | PREFERENTIAL DISPLAY | September 2001 | April 2004 | Allow | 31 | 3 | 0 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner BABIC, CHRISTOPHER M.
With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner BABIC, CHRISTOPHER M works in Art Unit 1633 and has examined 63 patent applications in our dataset. With an allowance rate of 25.4%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 40 months.
Examiner BABIC, CHRISTOPHER M's allowance rate of 25.4% places them in the 3% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by BABIC, CHRISTOPHER M receive 2.17 office actions before reaching final disposition. This places the examiner in the 59% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by BABIC, CHRISTOPHER M is 40 months. This places the examiner in the 23% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +50.0% benefit to allowance rate for applications examined by BABIC, CHRISTOPHER M. This interview benefit is in the 93% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 5.6% of applications are subsequently allowed. This success rate is in the 2% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 10.0% of cases where such amendments are filed. This entry rate is in the 10% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 1% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 0.0% of appeals filed. This is in the 0% percentile among all examiners. Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.
When applicants file petitions regarding this examiner's actions, 100.0% are granted (fully or in part). This grant rate is in the 89% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 9.5% of allowed cases (in the 93% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.